Ridwelski 2008.
Methods | Multicentre RCT 2 arms Quality score: B | |
Participants | n = 273 Median age: 62 years Metastatic disease: 90% | |
Interventions | DC: docetaxel 75 mg/m² + cisplatin 75 mg/m² d 1, repeated at 3 w FLC: 5‐FU 2000 mg/m² + leucovorin 500 mg/m² d 1, 8, 15, 22, 29, 36, repeated at 7 w + cisplatin 50 mg/m² d 1, 15, 29, repeated at 7 w (cisplatin omitted in FLC in cycle 4) |
|
Outcomes | Median overall and hazard ratios for survival and time to progression 1‐year survival Tumour response Toxicity | |
Notes | Study currently published as abstract only. Information on final results provided by first author. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Random number tables |
Allocation concealment (selection bias) | Low risk | Central |
Incomplete outcome data (attrition bias) efficacy | Low risk | Analysis for all randomised and screened patients |
Incomplete outcome data (attrition bias) safety | Low risk | Analysis for all randomised, screened and treated patients |
Selective reporting (reporting bias) | Low risk | Report includes all expected outcomes |
Other bias | Unclear risk | N/A |
Blinded review of CT/MRI‐scans? | High risk | Per first author |